Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer

Hubert G. Hotz, O. Joe Hines, Birgit Hotz, Thomas Foitzik, Heinz J. Buhr, Howard A. Reber, K. S. Kirkwood, Murray Korc, L. William Traverso

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Blockade of vascular endothelial growth factor (VEGF) and inhibition of matrix metalloproteinases (MMP) are promising therapies for cancer. This study assessed the effects of a neutralizing anti-VEGF antibody (A4.6.1) and an MMP inhibitor (BB-94) on pancreatic cancer (PaCa) in vivo. Five million cells of two human PaCa cell lines (AsPC-1 and HPAF-2) were injected subcutaneously into nude mice; 1 mm3 fragments of the resulting tumors were implanted into the pancreas of other mice. Animals were randomized into a control group and three treatment groups: A4.6.1 (100 μg intraperitoneally twice weekly); BB-94 (50 mg/kg every other day); and combination (A4.6.1 plus BB-94). Treatment was started after 3 days and continued for 14 weeks. Tumor volume, local and distant spread (score), and ascites were determined at autopsy. Microvessel density as a parameter of neoangiogenesis was analyzed in CD31-stained tumor sections. Both monotherapies reduced tumor volume (HPAF-2: -89% by A4.6.1 and -75% by BB-94; AsPC-1: -48% by A4.6.1 and -72% by BB-94), spread (HPAF-2: -76% by A4.6.1 and -58% by BB-94; AsPC-1: -32% by A4.6.1 and -54% by BB-94), and microvessel density (HPAF-2: -75% by A4.6.1 and -30% by BB-94; AsPC-1: -59% by A4.6.1 and -30% by BB-94), resulting in a tendency toward increased survival (HPAF-2: 8 of 8 animals by A4.6.1 or BB-94 vs. 4 of 8; AsPC-1: 3 of 8 by A4.6.1, 4 of 8 by BB-94 vs. 1 of 8). Combination therapy yielded additional effects in the HPAF-2 group with regard to tumor volume (-95%) and development of ascites (0 of 8 vs. 2 of 8 by A4.6.1 or BB-94 vs. 5 of 8 control mice). Both VEGF blockade and MMP inhibition reduce primary tumor size, metastasis, and angiogenesis, thereby increasing survival in experimental pancreatic cancer. Combination treatment results in additive effects in moderately differentiated HPAF-2 tumors.

Original languageEnglish (US)
Pages (from-to)220-228
Number of pages9
JournalJournal of Gastrointestinal Surgery
Volume7
Issue number2
DOIs
StatePublished - Feb 2003
Externally publishedYes

Fingerprint

Investigational Therapies
Matrix Metalloproteinases
Pancreatic Neoplasms
Vascular Endothelial Growth Factor A
Tumor Burden
Neoplasms
Microvessels
Ascites
batimastat
Matrix Metalloproteinase Inhibitors
Therapeutics
Nude Mice
Pancreas
Autopsy

Keywords

  • Angiogenesis
  • Matrix metalloproteinases
  • Pancreatic cancer
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Surgery

Cite this

Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. / Hotz, Hubert G.; Hines, O. Joe; Hotz, Birgit; Foitzik, Thomas; Buhr, Heinz J.; Reber, Howard A.; Kirkwood, K. S.; Korc, Murray; Traverso, L. William.

In: Journal of Gastrointestinal Surgery, Vol. 7, No. 2, 02.2003, p. 220-228.

Research output: Contribution to journalArticle

Hotz, Hubert G. ; Hines, O. Joe ; Hotz, Birgit ; Foitzik, Thomas ; Buhr, Heinz J. ; Reber, Howard A. ; Kirkwood, K. S. ; Korc, Murray ; Traverso, L. William. / Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. In: Journal of Gastrointestinal Surgery. 2003 ; Vol. 7, No. 2. pp. 220-228.
@article{a14ec43014a147d78c2fa06f0dfd98b4,
title = "Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer",
abstract = "Blockade of vascular endothelial growth factor (VEGF) and inhibition of matrix metalloproteinases (MMP) are promising therapies for cancer. This study assessed the effects of a neutralizing anti-VEGF antibody (A4.6.1) and an MMP inhibitor (BB-94) on pancreatic cancer (PaCa) in vivo. Five million cells of two human PaCa cell lines (AsPC-1 and HPAF-2) were injected subcutaneously into nude mice; 1 mm3 fragments of the resulting tumors were implanted into the pancreas of other mice. Animals were randomized into a control group and three treatment groups: A4.6.1 (100 μg intraperitoneally twice weekly); BB-94 (50 mg/kg every other day); and combination (A4.6.1 plus BB-94). Treatment was started after 3 days and continued for 14 weeks. Tumor volume, local and distant spread (score), and ascites were determined at autopsy. Microvessel density as a parameter of neoangiogenesis was analyzed in CD31-stained tumor sections. Both monotherapies reduced tumor volume (HPAF-2: -89{\%} by A4.6.1 and -75{\%} by BB-94; AsPC-1: -48{\%} by A4.6.1 and -72{\%} by BB-94), spread (HPAF-2: -76{\%} by A4.6.1 and -58{\%} by BB-94; AsPC-1: -32{\%} by A4.6.1 and -54{\%} by BB-94), and microvessel density (HPAF-2: -75{\%} by A4.6.1 and -30{\%} by BB-94; AsPC-1: -59{\%} by A4.6.1 and -30{\%} by BB-94), resulting in a tendency toward increased survival (HPAF-2: 8 of 8 animals by A4.6.1 or BB-94 vs. 4 of 8; AsPC-1: 3 of 8 by A4.6.1, 4 of 8 by BB-94 vs. 1 of 8). Combination therapy yielded additional effects in the HPAF-2 group with regard to tumor volume (-95{\%}) and development of ascites (0 of 8 vs. 2 of 8 by A4.6.1 or BB-94 vs. 5 of 8 control mice). Both VEGF blockade and MMP inhibition reduce primary tumor size, metastasis, and angiogenesis, thereby increasing survival in experimental pancreatic cancer. Combination treatment results in additive effects in moderately differentiated HPAF-2 tumors.",
keywords = "Angiogenesis, Matrix metalloproteinases, Pancreatic cancer, Vascular endothelial growth factor",
author = "Hotz, {Hubert G.} and Hines, {O. Joe} and Birgit Hotz and Thomas Foitzik and Buhr, {Heinz J.} and Reber, {Howard A.} and Kirkwood, {K. S.} and Murray Korc and Traverso, {L. William}",
year = "2003",
month = "2",
doi = "10.1016/S1091-255X(02)00157-9",
language = "English (US)",
volume = "7",
pages = "220--228",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer

AU - Hotz, Hubert G.

AU - Hines, O. Joe

AU - Hotz, Birgit

AU - Foitzik, Thomas

AU - Buhr, Heinz J.

AU - Reber, Howard A.

AU - Kirkwood, K. S.

AU - Korc, Murray

AU - Traverso, L. William

PY - 2003/2

Y1 - 2003/2

N2 - Blockade of vascular endothelial growth factor (VEGF) and inhibition of matrix metalloproteinases (MMP) are promising therapies for cancer. This study assessed the effects of a neutralizing anti-VEGF antibody (A4.6.1) and an MMP inhibitor (BB-94) on pancreatic cancer (PaCa) in vivo. Five million cells of two human PaCa cell lines (AsPC-1 and HPAF-2) were injected subcutaneously into nude mice; 1 mm3 fragments of the resulting tumors were implanted into the pancreas of other mice. Animals were randomized into a control group and three treatment groups: A4.6.1 (100 μg intraperitoneally twice weekly); BB-94 (50 mg/kg every other day); and combination (A4.6.1 plus BB-94). Treatment was started after 3 days and continued for 14 weeks. Tumor volume, local and distant spread (score), and ascites were determined at autopsy. Microvessel density as a parameter of neoangiogenesis was analyzed in CD31-stained tumor sections. Both monotherapies reduced tumor volume (HPAF-2: -89% by A4.6.1 and -75% by BB-94; AsPC-1: -48% by A4.6.1 and -72% by BB-94), spread (HPAF-2: -76% by A4.6.1 and -58% by BB-94; AsPC-1: -32% by A4.6.1 and -54% by BB-94), and microvessel density (HPAF-2: -75% by A4.6.1 and -30% by BB-94; AsPC-1: -59% by A4.6.1 and -30% by BB-94), resulting in a tendency toward increased survival (HPAF-2: 8 of 8 animals by A4.6.1 or BB-94 vs. 4 of 8; AsPC-1: 3 of 8 by A4.6.1, 4 of 8 by BB-94 vs. 1 of 8). Combination therapy yielded additional effects in the HPAF-2 group with regard to tumor volume (-95%) and development of ascites (0 of 8 vs. 2 of 8 by A4.6.1 or BB-94 vs. 5 of 8 control mice). Both VEGF blockade and MMP inhibition reduce primary tumor size, metastasis, and angiogenesis, thereby increasing survival in experimental pancreatic cancer. Combination treatment results in additive effects in moderately differentiated HPAF-2 tumors.

AB - Blockade of vascular endothelial growth factor (VEGF) and inhibition of matrix metalloproteinases (MMP) are promising therapies for cancer. This study assessed the effects of a neutralizing anti-VEGF antibody (A4.6.1) and an MMP inhibitor (BB-94) on pancreatic cancer (PaCa) in vivo. Five million cells of two human PaCa cell lines (AsPC-1 and HPAF-2) were injected subcutaneously into nude mice; 1 mm3 fragments of the resulting tumors were implanted into the pancreas of other mice. Animals were randomized into a control group and three treatment groups: A4.6.1 (100 μg intraperitoneally twice weekly); BB-94 (50 mg/kg every other day); and combination (A4.6.1 plus BB-94). Treatment was started after 3 days and continued for 14 weeks. Tumor volume, local and distant spread (score), and ascites were determined at autopsy. Microvessel density as a parameter of neoangiogenesis was analyzed in CD31-stained tumor sections. Both monotherapies reduced tumor volume (HPAF-2: -89% by A4.6.1 and -75% by BB-94; AsPC-1: -48% by A4.6.1 and -72% by BB-94), spread (HPAF-2: -76% by A4.6.1 and -58% by BB-94; AsPC-1: -32% by A4.6.1 and -54% by BB-94), and microvessel density (HPAF-2: -75% by A4.6.1 and -30% by BB-94; AsPC-1: -59% by A4.6.1 and -30% by BB-94), resulting in a tendency toward increased survival (HPAF-2: 8 of 8 animals by A4.6.1 or BB-94 vs. 4 of 8; AsPC-1: 3 of 8 by A4.6.1, 4 of 8 by BB-94 vs. 1 of 8). Combination therapy yielded additional effects in the HPAF-2 group with regard to tumor volume (-95%) and development of ascites (0 of 8 vs. 2 of 8 by A4.6.1 or BB-94 vs. 5 of 8 control mice). Both VEGF blockade and MMP inhibition reduce primary tumor size, metastasis, and angiogenesis, thereby increasing survival in experimental pancreatic cancer. Combination treatment results in additive effects in moderately differentiated HPAF-2 tumors.

KW - Angiogenesis

KW - Matrix metalloproteinases

KW - Pancreatic cancer

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0038501002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038501002&partnerID=8YFLogxK

U2 - 10.1016/S1091-255X(02)00157-9

DO - 10.1016/S1091-255X(02)00157-9

M3 - Article

C2 - 12600446

AN - SCOPUS:0038501002

VL - 7

SP - 220

EP - 228

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 2

ER -